Information about Trelegy Ellipta Inhaler (Fluticasone/Umeclidinium/Vilanterol)
Trelegy Ellipta is a combination inhaler containing three active ingredients: fluticasone, umeclidinium, and vilanterol. It is used for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. The combination works by reducing inflammation, relaxing airway muscles, and improving airflow to help ease breathing. Trelegy Ellipta is a once-daily inhaler, offering convenience for individuals managing chronic respiratory conditions.
Product Highlights
- Trelegy Ellipta is primarily used for the maintenance treatment of COPD, which includes chronic bronchitis and emphysema.
- It is also used for the maintenance treatment of asthma in patients who require a combination of inhaled corticosteroids and long-acting bronchodilators.
Key Ingredient
- Fluticasone
- Umeclidinium
- Vilanterol
Key Benefits
- Trelegy Ellipta is taken once a day, which helps with adherence to the treatment regimen.
- The combination of three active ingredients helps open the airways and reduce inflammation, improving airflow and making breathing easier.
- For patients with COPD, Trelegy Ellipta can help reduce flare-ups and the need for additional medication or hospitalization.
- By combining three mechanisms of action, Trelegy Ellipta addresses multiple aspects of asthma and COPD, offering a more comprehensive treatment approach.
Direction of Use
- Trelegy Ellipta is designed for inhalation only. Use the inhaler as directed by your healthcare provider, typically once a day, in the morning.
- To prepare the inhaler, open the device, slide the lever to load the dose, and breathe in deeply through the mouthpiece. Hold your breath for several seconds, then exhale gently. Follow the instructions provided with the inhaler for proper use.
- Clean the mouthpiece of the inhaler regularly as per the manufacturer's instructions to ensure the device functions properly.
Safety Concerns
- Like other inhalers, Trelegy Ellipta may cause side effects such as:
- Inhaled corticosteroids like fluticasone can increase the risk of fungal infections in the mouth. Rinse your mouth after using the inhaler to reduce this risk.
- In patients with COPD, Trelegy may increase the risk of pneumonia or other respiratory infections.
- Vilanterol (the LABA) may cause an increased heart rate or palpitations in some individuals.
- Long-term use of corticosteroids like fluticasone can affect bone density.
- Inhaled corticosteroids can sometimes lead to increased intraocular pressure, cataracts, or other eye issues.
- Trelegy Ellipta is not intended for relief of sudden breathing problems (acute bronchospasm). It is for daily maintenance and prevention.
- In rare cases, inhalers like Trelegy can cause paradoxical bronchospasm, where the airways constrict rather than relax. If this occurs, use of the medication should be stopped immediately, and alternative treatments should be considered.
Avoid Trelegy Ellipta Inhaler (Fluticasone/Umeclidinium/Vilanterol) If
- If you have a known allergy to any of the ingredients in Trelegy Ellipta, including fluticasone, umeclidinium, or vilanterol, you should avoid using this medication.
- Avoid Trelegy if you have a history of severe allergic reactions (anaphylaxis) to inhaled medications or other beta-agonists.
- Trelegy Ellipta is not suitable for treating acute bronchospasm or sudden asthma/COPD attacks. A fast-acting inhaler (such as a rescue inhaler) should be used instead.
- If you have certain heart conditions, such as arrhythmias (irregular heartbeats), avoid using Trelegy Ellipta without first consulting your healthcare provider, as the long-acting beta-agonist (vilanterol) may increase heart rate.
- If your asthma or COPD is not well-controlled with other medications, your healthcare provider may choose an alternative treatment plan rather than Trelegy Ellipta.
- Consult your doctor if you are pregnant, planning to become pregnant, or breastfeeding, as the safety of Trelegy Ellipta during pregnancy and lactation has not been established.
